Medical Research Council (United Kingdom)

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

Retrieved on: 
Tuesday, May 30, 2023
University, GSK, Defecation, Medical Research Council, Research, Audit committee, Alkermes, Patient, School, Pharmacy school, AMAG Pharmaceuticals, Therapy, Medical Research Council (United Kingdom), Pharmaceutical industry, Nursing, Pharmacy, Ulcerative colitis

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee.

Key Points: 
  • NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee.
  • “Dr.
  • Batycky is an accomplished biopharmaceutical executive and an important addition to Landos’ Board,” said Gregory Oakes, President and CEO of Landos.
  • Prior to this, she held executive leadership positions at various biopharmaceutical companies including Ohana Biosciences, Akashi Therapeutics, Warp Drive Bio and AMAG Pharmaceuticals.

Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King’s College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer

Retrieved on: 
Wednesday, March 8, 2023
Therapy, Medical Research Council (United Kingdom), UK Research and Innovation, Neuroendocrine cell, Pancreas, CATX, Neoplasm, NYSE, Cancer, NETS, Senior lecturer, Isotope, Appendix, Radiation, Tissue, Cell, Medical Research Council, Patient, Associate, Auger, Rectum, Glomus tumor, MRC, Travel, Perspective, UKRI, United Kingdom, Radiobiology, Pharmaceutical industry, Medical imaging, IOWA, Research

RICHLAND, WASHINGTON & CORALVILLE, IOWA, March 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (formerly known as “Isoray, Inc.”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the awarding of a $1 million research grant from the Medical Research Council (MRC), part of UK Research and Innovation (UKRI) (www.ukri.org), to collaborator Samantha Terry PhD, Associate Professor (Senior Lecturer) at King’s College London.

Key Points: 
  • “My research is focused on the interactions of radiation with cells at a fundamental level.
  • Under the project, Perspective Therapeutics’ scientists will collaborate on radiobiology research, and provide isotopes and peptide precursors.
  • Perspective Therapeutics is supporting a graduate student working toward a doctorate in radiobiology under the guidance of Dr. Terry.
  • We are excited to be part of the research project and providing support for thought leading scientists in this area of research.”

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

Retrieved on: 
Thursday, March 9, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Swiss Cancer League, MD, Virology, McGill University, University School, The Ottawa Hospital, Oklahoma State University College of Agricultural Sciences and Natural Resources, Jennerex, Journal, CD8, Therapy, Euronext Paris, University of Ottawa Faculty of Medicine, Ottawa Hospital Research Institute, Research, School, OHRI, Medical Research Council, Potyvirus, Publication, New York University Grossman School of Medicine, National university, Agriculture Network Information Center, Clinical, Biochemistry, University, LICR, CTL, Immunotherapy, University of Lausanne, OV, Faculty, Doctor of Philosophy, Medical Research Council (United Kingdom), Épalinges, Ludwig Cancer Research, McMaster University, Pharmaceutical industry, Science, Medicine, Biology, Cancer, Nature

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.

Key Points: 
  • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the appointment of Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors.
  • “John and Pedro are world leaders in cancer immunotherapy, and will bring considerable expertise to Transgene,” said Hedi Ben Brahim, Transgene’s CEO.
  • He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics.
  • Pedro obtained his MD at the School of Medicine of the National University of Colombia in Bogota.

New Data Links Modulation of Key Immune-Related Proteins to Improvement of Specific Symptoms in Long COVID

Retrieved on: 
Thursday, February 16, 2023
COVID-19, Research, Infectious Diseases, Biotechnology, Other Health, Health, General Health, Other Science, Science, Biomarker, PASC, Fatigue, NYHA, Trial of the century, Randomized controlled trial, Frontiers in Medicine, Diagnosis, Patient, MRC, Timeline of the COVID-19 pandemic in the United Kingdom, FSS, Medical Research Council (United Kingdom), New York Heart Association Functional Classification, Georgetown University School of Nursing, Medical Research Council, COMPASS, CDC, Survivor, Modified Rankin Scale, DSM-IV codes, Chronic, ME/CFS, Pravastatin, Clinical descriptions of chronic fatigue syndrome, Community, Alternative medicine, Classification, Pharmaceutical industry, Medical imaging, Maraviroc, COVID, Medicine

Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID (PASC), commonly known as long COVID.

Key Points: 
  • Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID (PASC), commonly known as long COVID.
  • The study results, published in Frontiers in Medicine, also support a precision medicine approach to diagnosis of long COVID as well as differentiation of long COVID from ME-CFS (myalgic encephalomyelitis/chronic fatigue syndrome), which presents with similar symptoms.
  • Subjective neurological, autonomic, respiratory, cardiac and fatigue symptoms scores all decreased by statistically significant margins.
  • In particular, the FSS (fatigue being the most common symptom) decreased and was closely correlated in decreases of IL-2 and TNF-α.

Seeking Canadian innovators for $6.4 million prize to develop life-changing technology for people with dementia

Retrieved on: 
Saturday, July 30, 2022
Weston Family Foundation, Dementia, Innovation, Tom Hunter, Network, Global health, Farmer, Innovate UK, Organic, CEO, Medical Research Council (United Kingdom), Government, Research, Alzheimer Society of Ontario, Solution, Medical Research Council, Artificial intelligence, Climate change, Health, Longitude Prize, Technology, Machine learning, Society, Ageing, Intelligence, Alzheimer's Society, Disease, Caregiver, Ecosystem, Science, Memory, Global Affairs Canada, Life, Indigenous self-government in Canada, Center, MRC, Growth, CAD, NEPAD African Western and Southern Networks of Centres of Excellence in Water Sciences, Residential care, Video game, Pharmaceutical industry, Creative industries, Renewable energy, Alzheimer's disease

TORONTO, July 30, 2022 /CNW/ - AGE-WELL is joining forces with Challenge Works to support the new 4.1 million ($6.4 million CAD1) Longitude Prize on Dementia which will reward innovators developing assistive technologies for people living with dementia.

Key Points: 
  • TORONTO, July 30, 2022 /CNW/ - AGE-WELL is joining forces with Challenge Works to support the new 4.1 million ($6.4 million CAD1) Longitude Prize on Dementia which will reward innovators developing assistive technologies for people living with dementia.
  • The 4.1 million Longitude Prize on Dementia will award 3.1 million ($4.8 million CAD) in seed funding and grants to the most promising innovators, with a 1 million ($1.6 million CAD) prize awarded to the winner in early 2026.
  • Funded by Alzheimer's Society - the UK's leading dementia charity - and Innovate UK - the UK government's innovation agency - the Longitude Prize on Dementia is delivered by global challenge prize experts, Challenge Works.
  • To date, it has distributed 84 million ($130 million CAD)in funding and engaged with 12,000 innovators.

PepGen Appoints Caroline Godfrey, Ph.D. to the Company’s Scientific Advisory Board

Retrieved on: 
Friday, July 22, 2022
EDO, University, GLOBE, University College London, SEC, Medical Research Council (United Kingdom), Research, Form 10-Q, Genetics, Private Securities Litigation Reform Act, Medical Research Council, Coronavirus Scientific Advisory Board (Turkey), Technology, Science, Neuromuscular Disorders, Patient, Therapy, Innovation, UK Research and Innovation, Neuromuscular disease, Peptide, Form, Pharmaceutical industry, Management, Fine chemical, Discovery

In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.

Key Points: 
  • In connection with this appointment, Dr. Godfrey leaves her position as Senior Vice President of Discovery at PepGen.
  • Caroline is one of our scientific co-founders, and was appointed as the first Chief Executive Officer of PepGen following the companys spinout from the University of Oxford and the Medical Research Council of United Kingdom Research and Innovation.
  • We are incredibly grateful for all that Caroline has done for PepGen and look forward to her continued contributions.
  • Im excited to be moving into a new position on PepGens Scientific Advisory Board, said Dr. Godfrey.

Diadem Partners with Dementias Platform UK to Advance Diagnosis and Treatment of Alzheimer's Disease

Retrieved on: 
Monday, June 13, 2022
Dementia, Research, Government budget balance, Knowledge, Disease, Partnership, Gaps, Environment, Organization, University, MRC, Patient, AD, Technology, Medical Research Council, Adoption, Incidence, Diagnosis, Industry, Population, Medical Research Council (United Kingdom), Pharmaceutical industry, Medical imaging, Alzheimer's disease, Diadem

MILAN, June 13, 2022 /PRNewswire/ -- Diadem SpA, a company developing AlzoSure® Predict, the first blood-based test for the early prediction of progression to Alzheimer's disease (AD), today announced that is has joined Dementias Platform UK (DPUK) as a corporate partner.

Key Points: 
  • It offers facilitated access to detailed information on more than three million individuals from 50 long-term health cohort studies.
  • "We welcome the opportunity to join this unique network of research institutions and healthcare companies working together to transform the diagnosis and treatment of dementia," said Paul Kinnon, Chief Executive Officer of Diadem.
  • The company is developing the first blood-based prognostic test for the early detection of dementia, with a focus on Alzheimer's disease.
  • Diadem is preparing for commercialisation of AlzoSurePredict in collaboration with global strategic partners.

HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors

Retrieved on: 
Wednesday, May 18, 2022
Photon, Cancer, Cardiff University, A*STAR, Francis Crick Institute, NASH, PMO, Agency for Science, Technology and Research, Scottish Science Advisory Council, Agency, Director, Multimedia, Patient, Medical Research Council, Prime Minister's Office (India), Commander, Health, General of the branch, List of life sciences, Bristol Myers Squibb, Health care, Medical Research Council (United Kingdom), Non-alcoholic fatty liver disease, Artificial intelligence, Technology, Algorithm, Johnson & Johnson, FDA, CBE, Cros, Smith & Nephew, Board, Public Service Medal, Digital health, Drug development, Adoption, GE Healthcare, TPE, Trustee, Drug discovery, SHG, Medical device, Pharmaceutical industry, Research, Science

John brings with him a global and diverse experience in life sciences, along with a deep interest in healthcare technologies to improve clinical standards and care for patients.

Key Points: 
  • John brings with him a global and diverse experience in life sciences, along with a deep interest in healthcare technologies to improve clinical standards and care for patients.
  • John will provide guidance to the senior management at HistoIndex to transform histopathological standards in diagnostics and drug development with the global adoption of stain-free AI digital pathology for fibrotic diseases.
  • In 2012, John was awarded the Commander of the Order of the British Empire (CBE) for his significant contributions to Life Sciences, Healthcare and Science.
  • Says Dr. Gideon Ho, Chief Executive Officer of HistoIndex, "All of us at HistoIndex are very delighted to welcome Dr. John Jeans, a renowned thought leader and visionary in the life sciences space.

HistoIndex Welcomes Life Sciences and MedTech Visionary, David John Jeans CBE, to Board of Directors

Retrieved on: 
Wednesday, May 18, 2022
Photon, Cancer, Cardiff University, A*STAR, Francis Crick Institute, NASH, PMO, Agency for Science, Technology and Research, Scottish Science Advisory Council, Agency, Director, Patient, Medical Research Council, Prime Minister's Office (India), Commander, Health, General of the branch, List of life sciences, Bristol Myers Squibb, Health care, Medical Research Council (United Kingdom), Non-alcoholic fatty liver disease, Artificial intelligence, Technology, Algorithm, Johnson & Johnson, FDA, CBE, Cros, Smith & Nephew, Board, Public Service Medal, Digital health, Drug development, Adoption, GE Healthcare, TPE, Trustee, Drug discovery, SHG, Medical device, Pharmaceutical industry, Research, Science

John brings with him a global and diverse experience in life sciences, along with a deep interest in healthcare technologies to improve clinical standards and care for patients.

Key Points: 
  • John brings with him a global and diverse experience in life sciences, along with a deep interest in healthcare technologies to improve clinical standards and care for patients.
  • John will provide guidance to the senior management at HistoIndex to transform histopathological standards in diagnostics and drug development with the global adoption of stain-free AI digital pathology for fibrotic diseases.
  • In 2012, John was awarded the Commander of the Order of the British Empire (CBE) for his significant contributions to Life Sciences, Healthcare and Science.
  • Says Dr. Gideon Ho, Chief Executive Officer of HistoIndex, "All of us at HistoIndex are very delighted to welcome Dr. John Jeans, a renowned thought leader and visionary in the life sciences space.

Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Retrieved on: 
Wednesday, March 16, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Degenerative disease, Mortality, University, New product development, EGFR, MDRD, Renal replacement therapy, Death, Disease, Patient, Heart, Heart failure, Glomerular filtration rate, Multimedia, Boehringer Ingelheim, Obesity, LLY, Cardiovascular disease, EMPA, Dialysis, Kidney transplantation, MRC, Safety, Hospital, Medical Research Council (United Kingdom), Corporation, Chronic kidney disease, Lilly, Eli Lilly and Company, EMPOWER, CKD, Medical Research Council, SGLT2, NYSE, Albuminuria, Kidney, Diabetes, Pharmaceutical industry, Kidney disease, Diet

The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trials Independent Data Monitoring Committee.

Key Points: 
  • The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trials Independent Data Monitoring Committee.
  • The trial includes people:1,2
    - with and without diabetes;
    - with CKD attributable to a wide range of underlying causes.
  • The primary endpoint of the trial is a composite of kidney disease progression* or cardiovascular death.
  • The early stop of the trial is a tremendous step toward our goal of improving the lives of adults living with kidney disease.